Rofecoxib is a nonsteroidal anti-inflammatory drug (NSAID) developed by Merck & Co. to treat osteoarthritis, acute pain conditions, and dysmenorrhoea. Rofecoxib was approved as safe and effective by the Food and Drug Administration (FDA) on May 20, 1999 and was subsequently marketed under the brand name Vioxx®, Ceoxx® and Ceeoxx®.
Rofecoxib gained widespread acceptance among physicians treating patients with arthritis and other conditions causing chronic or acute pain. Worldwide, over 80 million people were prescribed rofecoxib at some time.
On September 30, 2004, Merck voluntarily withdrew rofecoxib from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use. Rofecoxib was one of the most widely used drugs ever to be withdrawn from the market. In the year before withdrawal, Merck had sales revenue of US$2.5 billion from Vioxx.
|
09/04/2010 11:34 AM
|
|
Accident Raises Safety Concerns About Chinese Tires
|
Wall Street Journal reports that more than 450,000 Chinese-made tires may lack an important safety feature.
|
|
09/04/2010 11:34 AM
|
|
Accident Raises Safety Concerns About Chinese Tires
|
Wall Street Journal reports that more than 450,000 Chinese-made tires may lack an important safety feature
|
|
09/04/2010 11:34 AM
|
|
Vioxx jury awards $20M to Idaho couple
|
Merck & Co.'s painkiller Vioxx contributed to an Idaho postal worker's heart attack, a jury in Atlantic City ruled Monday, reversing the verdict in the man's first trial and awarding him and his wife...
|
|
09/04/2010 11:34 AM
|
|
Jury blames Vioxx for man's heart attack, awards $20M
|
Merck's former painkiller Vioxx contributed to the heart attack of an Idaho postal worker, a state jury in Atlantic City ruled Monday. The jury awarded Frederick "Mike" Humeston and his wife $20 milli...
|
|
09/04/2010 11:34 AM
|
|
Merck's New Painkiller May Have Same Risks as Vioxx (Update1)
|
Sept. 13 (Bloomberg) -- Merck & Co.'s experimental painkiller, Arcoxia, may carry the same risk of heart attacks and strokes as Vioxx, according to an analysis of 23 studies comparing side effects of ...
|
|
09/04/2010 11:34 AM
|
|
Merck's Vioxx Shown to Pose Heart and Kidney Risks
|
Judith Levy submits: Excerpt from our One Page Annotated Wall Street Journal Summary : Merck's Vioxx Tied to New Threat; Heart Risks Start Early in Study Summary: Two studies published online yesterd...
|
|
09/04/2010 11:34 AM
|
|
Vioxx?s Risks May Be More Than Others, Studies Find
|
A paper published Tuesday suggests that Vioxx posed heart risks that a similar drug, Celebrex, does not.
|
|
09/04/2010 11:34 AM
|
|
Studies unveil more Vioxx risk
|
CHICAGO (Reuters) -- Two studies offer more evidence about the dangers of some painkillers, adding kidney problems to heart concerns already raised with the drug once sold as Vioxx, researchers said o...
|
|
09/04/2010 11:34 AM
|
|
Vioxx Most Dangerous Cox-2 Drug: Studies
|
TUESDAY, Sept. 12 (HealthDay News) -- Two studies suggest that the banned prescription painkiller Vioxx was more dangerous for users than its two cox-2 inhibitor rivals, Bextra, also withdrawn, and t...
|
|
09/04/2010 11:34 AM
|
|
Vioxx Trial Verdict in Favor of Defendant Merck Vacated
|
Seeger Weiss LLP announces that the jury verdict rendered in favor of Merck & Co. (NYSE: MRK) in the Vioxx-related trial entitled, Humeston v. Merck, has been vac...
|
|
09/04/2010 11:34 AM
|
|
Merck hit by double setback over Vioxx
|
Merck & Co. on Thursday suffered a double setback when a federal jury awarded $51 million to a former user of its withdrawn pain medicine Vioxx, and a New Jersey judge threw out a Vioxx verdict that ...
|
|
09/04/2010 11:34 AM
|
|
Merck loses Vioxx case, told to pay $51 million
|
A federal jury on Thursday found that Merck & Co. Inc. was negligent and knowingly made misrepresentations about its withdrawn pain medicine Vioxx, and awarded $51 million to the plaintiff.
|
|
09/04/2010 11:34 AM
|
|
New Jersey Vioxx Case Tossed
|
The judge in the first Vioxx case Merck won tosses the case on new evidence.
|
|
09/04/2010 11:34 AM
|
|
Merck hit by double setback over Vioxx
|
Merck & Co. on Thursday suffered a double setback when a federal jury awarded $51 million to a former user of its withdrawn pain medicine Vioxx, and a New Jersey judge threw out a Vioxx verdict that ...
|
|
09/04/2010 11:34 AM
|
|
Merck loses Vioxx case, told to pay $51 million
|
A federal jury on Thursday found that Merck & Co. Inc. was negligent and knowingly made misrepresentations about its withdrawn pain medicine Vioxx, and awarded $51 million to the plaintiff.
|
